The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 276-280

  Ebermann, Linda ^a   Spillmann, Frank ^a   Sidiropoulos, Melanie ^a   Escher, Felicitas ^a   Heringer Walther, Silvia ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a   Walther, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin (1 7); Diabetes; Renin angiotensin system; Systolic dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG MECHANISM; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART RATE; HEMODYNAMICS; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; HEART; IMIDAZOLES; MALE; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; STREPTOZOCIN; VENTRICULAR FUNCTION, LEFT;

EID: 48049120612     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.024     Document Type: Article

References (36)

1. Bauters C., Lamblin N., McFadden E.P., Van Belle E., Millaire A., and De Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc. Diabetol. 2 (2003) 1 (Online)
2. Benter I.F., Yousif M.H.M., Cojocel C., al-Maghrebi M., and Diz D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) 666-672
3. Brosnihan K.B., Li P., and Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27 (1996) 523-528
4. Cai L., and Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 1 (2001) 181-193
5. Campbell D.J., Kladis A., and Duncan A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23 (1994) 439-449
6. Ferrario C.M. Angiotensin I, angiotensin II and their biologically active peptides. J. Hypertens. 20 (2002) 805-807
7. Fiordaliso F., Li B., Latini R., Sonnenblick E.H., Anversa P., Leri A., and Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab. Invest. 80 (2000) 513-527
8. Gembardt, F., Heringer-Walther, S., van Esch, J.H., Sterner-Kock, A., van Veghel, R., Le, T.H., Garrelds, I.M., Coffman, T.M., Danser, A.H., Schultheiss, H.P., Walther, T., in press. Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors. FASEB J. doi:10.1096/fj.08-108316.
9. Janssens S., Pokreisz P., Schoonjans L., Pellens M., Vermeersch P., Tjwa M., Jans P., Scherrer-Crosbie M., Picard M.H., Szelid Z., Gillijns H., Van de Werf F., Collen D., and Bloch K.D. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ. Res. 94 9 (2004) 1256-1262
10. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34 (1974) 29-34
11. Kohara K., Brosnihan K.B., and Ferrario C.M. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 14 5 (1993) 883-891
12. Langeveld B., van Gilst W.H., Tio R.A., Zijlstra F., and Roks A.J. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45 1 (2005) 138-141
13. Lemos V.S., Silva D.M., Walther T., Alenina N., Bader M., and Santos R.A. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 46 3 (2005) 274-279
14. Li P., Chappell M.C., Ferrario C.M., and Brosnihan K.B. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29 (1997) 394-400
15. Loot A.E., Roks A., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., and van Gilst W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
16. Manolis A.J., Iraklianou S., Pittaras A., Zaris M., Tsioufis K., Psaltiras G., Psomali D., Foussas S., Gavras I., and Gavras H. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am. J. Hypertens. 18 (2005) 18-22
17. Metzger R., Bader M., Ludwig T., Berberich C., Bunnemann B., and Ganten D. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett. 357 1 (1995) 27-32
18. Modrak J. Collagen metabolism in the myocardium from streptozotocin-diabetic rats. Diabetes 29 (1980) 547-550
19. Monkemann H., De Vriese A.S., Blom H.J., Kluijtmans L.A., Heil S.G., Schild H.H., and Golubnitschaja O. Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids 23 (2002) 331-336
20. Peiro C., Vallejo S., Gembardt F., Azcutia V., Heringer-Walther S., Rodriguez-Manas L., Schultheiss H.P., Sanchez-Ferrer C.F., and Walther T. Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J. Hypertens. 25 12 (2007) 2421-2425
21. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., and Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 (1996) 841-842
22. Rosen R., Rump A.F., and Rosen P. The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. Diabetologia 38 (1995) 509-517
23. Santos R.A.S., Simões e Silva A.C., Magaldi A.J., Khosla M.C., Cesar K.R., Passaglio K.T., and Baracho N.C. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 27 (1996) 875-884
24. Santos R.A.S., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Nat. Acad. Sci. USA 100 (2003) 8258-8263
25. Tallant E.A., Ferrario C.M., and Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through inactivation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289 4 (2005) H1560-1566
26. Tschöpe C., Walther T., Yu M., Reinicke A., Koch M., Seligman C., Heringer S.B., Pesquero J.B., Bader M., Schultheiss H.P., and Unger T. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology 44 (1999) 35-42
27. Tschöpe C., Heringer-Walther S., Koch M., Spillmann F., Wendorf M., Hauke D., Bader M., Schultheiss H.P., and Walther T. Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J. Hypertens. 18 2 (2000) 223-228
28. Villar A.J., and Pedersen R.A. Parental imprinting of the Mas protooncogene in mouse. Nat. Genet. 8 (1994) 373-379
29. Walther T., Balschun D., Voigt J.P., Fink H., Zuschratter W., Birchmeier C., Ganten D., and Bader M. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273 (1998) 11867-11873
30. Walther T., Wessel N., Kang N., Sander A., Tschöpe C., Malberg H., Bader M., and Voss A. Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz. J. Med. Biol. Res. 33 1 (2000) 1-9
31. Walther T., Voigt J.P., Fink H., and Bader M. Sex specific behavioural alterations in Mas-deficient mice. Behav. Brain Res. 107 (2000) 105-109
32. Wang Y., de Waard M.C., Sterner-Kock A., Stepan H., Schultheiss H.P., Duncker D.J., and Walther T. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur. J. Heart Fail. 9 (2007) 548-957
33. Wiemer G., Dobrucki L.W., Louka F.R., Malinski T., and Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40 (2002) 847-852
34. Wohaieb S.A., and Godin D.V. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat - effects of insulin treatment. Diabetes 36 (1987) 1014-1018
35. Young D., Waitches G., Birchmeier C., Fasano O., and Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45 (1986) 711-719
36. Zarich S.W., and Nesto R.W. Diabetic cardiomyopathy. Am. Heart J. 118 (1989) 1000-1012